Srinagar Magazine

DelveInsight’s “Myotonic Dystrophy Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Myotonic Dystrophy, historical and forecasted epidemiology as well as the Myotonic Dystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Get a Free sample for the Myotonic Dystrophy Market Report:

https://www.delveinsight.com/report-store/myotonic-dystrophy-market

Some of the key facts of the Myotonic Dystrophy Market Report:

• The Myotonic Dystrophy market size was valued approximately USD 89 million in 2023 and is anticipated to grow with a significant CAGR of 18.4% during the study period (2022-2036).

• In July 2026, Approximately 41% of patients with congenital myotonic dystrophy require hospitalization within a 12-month period, highlighting the significant burden of the disease. Against this backdrop, AMO Pharma, in collaboration with three major regulatory agencies, has agreed to use hospitalization as the primary efficacy endpoint in the registrational study of AMO-02. Rather than representing a regulatory compromise, this decision reflects a strategic approach to prioritize a clear, objective clinical outcome over composite functional measures, which can be challenging to standardize due to the highly variable presentation of the disease across patients and study sites.

• In March 2026, The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the FREEDOM2-DM1 trial due to concerns related to certain preclinical pharmacology and toxicology studies. The Phase 2 trial is designed as a multiple ascending dose study evaluating PGN-EDODM1 in patients with Myotonic Dystrophy Type 1 (DM1). Importantly, the partial hold does not involve any issues with the blinded clinical data from the earlier Phase 1 FREEDOM study, which had previously been submitted to support the initiation of the FREEDOM2 trial in the United States. As part of ongoing discussions with the FDA, PepGen is providing additional analyses, including newly unblinded data from the FREEDOM study.

• In February 2026, Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company focused on developing a novel class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™), announced that the final findings from the completed Phase 1/2 MARINA® clinical trial evaluating delpacibart etedesiran (del-desiran) in patients with Myotonic Dystrophy Type 1 will be published in the February 19 edition of The New England Journal of Medicine. The research article is titled “An Antibody Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.

• In June 2025, Dyne Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to DYNE-101 for treating myotonic dystrophy type 1 (DM1). The company also shared an updated strategy for pursuing US Accelerated Approval for DYNE-101 in DM1, following a Type C meeting with the FDA and the review of new long-term functional data.

• In April 2025, Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug Designation (ODD) to delpacibart etedesiran (del-desiran) for treating myotonic dystrophy type 1 (DM1). Del-desiran, an investigational therapy targeting the root cause of DM1—a progressive, often fatal neuromuscular disease with no approved treatments—is the first DM1 therapy to receive ODD in Japan. The drug has also received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the U.S. FDA, as well as Orphan designation from the European Medicines Agency (EMA).

• Within the 7MM, the EU4 and the UK accounted for approximately 353,191 diagnosed prevalent cases of Myotonic Dystrophy, with the number of cases projected to rise throughout the forecast period (2024–2036).

• Among the EU4 countries and the UK, Germany recorded the highest number of diagnosed prevalent Myotonic Dystrophy cases at 8,938 in 2023, followed by the UK and France. Conversely, Spain had the lowest diagnosed prevalent population within the EU4 and the UK that year.

• In 2023, Japan reported approximately 12,735 diagnosed prevalent cases of Myotonic Dystrophy, with these numbers projected to grow at a substantial CAGR.

• In 2023, Japan had roughly 1,834 myotonic dystrophy cases linked to gastrointestinal symptoms, 1,605 cases associated with cardiac dysrhythmias, 1,414 cases with sleep disorders, and 3,566 cases presenting other comorbidities.

• In 2023, adults accounted for the largest share of myotonic dystrophy cases in the 7MM, with an estimated 96,287 cases, compared to 9,075 cases among children.

• Key Myotonic Dystrophy Companies: EditForce, Inc., Arrowhead Pharmaceuticals, Inc., Vertex Pharmaceuticals, Pepgen Corporation, Avidity Biosciences, Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma, Dyne Therapeutics, Entrada Therapeutics, and others

• Key Myotonic Dystrophy Therapies: EF-210, ARO-DM1, VX-670, PGN-EDODM1, Delpacibart etedesiran, DM1 program, ENZ-001, JUV 161, DYNE-101, AOC 1001, Pitolisant, Tideglusib, Mexiletine, AMO-02, DYNE-101, ENTR-701, and others

• The Myotonic Dystrophy epidemiology based on gender analyzed that DM is more prevalent in adults (>18 years) than children (

• The Myotonic Dystrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myotonic Dystrophy pipeline products will significantly revolutionize the Myotonic Dystrophy market dynamics.

Myotonic Dystrophy Overview

Myotonic Dystrophy is a genetic disorder characterized by progressive muscle weakness and prolonged muscle contractions (myotonia). It affects multiple body systems, including the muscles, heart, eyes, and endocrine system. The condition is inherited and typically worsens over time, leading to difficulties with movement, coordination, and other complications such as cardiac issues and sleep disturbances. There are two main types Type 1 (DM1) and Type 2 (DM2) with DM1 being the more common and severe form.

To Know in detail about the Myotonic Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myotonic Dystrophy Market Forecast

Myotonic Dystrophy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Myotonic Dystrophy Epidemiology Segmentation:

The Myotonic Dystrophy market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalence of Myotonic Dystrophy

• Prevalent Cases of Myotonic Dystrophy by severity

• Gender-specific Prevalence of Myotonic Dystrophy

• Diagnosed Cases of Episodic and Chronic Myotonic Dystrophy

Download the report to understand which factors are driving Myotonic Dystrophy epidemiology trends @ Myotonic Dystrophy Epidemiology Forecast

Myotonic Dystrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myotonic Dystrophy market or expected to get launched during the study period. The analysis covers Myotonic Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Myotonic Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Myotonic Dystrophy Therapies and Key Companies

• EF-210: EditForce, Inc.

• ARO-DM1: Arrowhead Pharmaceuticals, Inc.

• VX-670: Vertex Pharmaceuticals

• PGN-EDODM1: Pepgen Corporation

• Delpacibart etedesiran: Avidity Biosciences

• DM1 program: Design Therapeutics

• ENZ-001: Enzerna

• JUV 161: Juvena Therapeutics

• DYNE-101: Dyne Therapeutics

• AOC 1001: Avidity Biosciences

• Pitolisant: Harmony Biosciences

• Tideglusib: AMO Pharma

• Mexiletine: Lupin

• AMO-02: AMO Pharma

• DYNE-101: Dyne Therapeutics

• ENTR-701: Entrada Therapeutics

Discover more about therapies set to grab major Myotonic Dystrophy market share @ Myotonic Dystrophy Treatment Market

Myotonic Dystrophy Market Drivers

• Increasing Disease Awareness: Improved recognition of Myotonic Dystrophy and enhanced diagnostic capabilities are supporting earlier diagnosis and treatment.

• Advancements in Genetic Research: Ongoing progress in gene-targeted therapies, antisense oligonucleotides, and RNA-based treatments is expanding the therapeutic pipeline.

• Growing Investment in Rare Disease Research: Increased funding from pharmaceutical companies and research organizations is accelerating drug development.

• Robust Clinical Pipeline: Multiple investigational therapies targeting the underlying genetic cause are expected to drive future market growth.

• Regulatory Incentives: Orphan drug designations, fast-track pathways, and other regulatory benefits encourage the development of novel therapies.

Myotonic Dystrophy Market Barriers

• Limited Approved Therapies: The absence of disease-modifying treatments continues to restrict market growth.

• Rare Disease Prevalence: A relatively small patient population limits commercial opportunities and clinical trial recruitment.

• High Development Costs: Developing therapies for rare neuromuscular disorders requires significant investment and extended timelines.

• Complex Disease Biology: Multisystem involvement and genetic complexity make therapeutic development challenging.

• Delayed Diagnosis: Misdiagnosis or late diagnosis due to variable clinical presentation can delay treatment initiation.

Scope of the Myotonic Dystrophy Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Myotonic Dystrophy Companies: EditForce, Inc., Arrowhead Pharmaceuticals, Inc., Vertex Pharmaceuticals, Pepgen Corporation, Avidity Biosciences, Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma, Dyne Therapeutics, Entrada Therapeutics, and others

• Key Myotonic Dystrophy Therapies: EF-210, ARO-DM1, VX-670, PGN-EDODM1, Delpacibart etedesiran, DM1 program, ENZ-001, JUV 161, DYNE-101, AOC 1001, Pitolisant, Tideglusib, Mexiletine, AMO-02, DYNE-101, ENTR-701, and others

• Myotonic Dystrophy Therapeutic Assessment: Myotonic Dystrophy current marketed and Myotonic Dystrophy emerging therapies

• Myotonic Dystrophy Market Dynamics: Myotonic Dystrophy market drivers and Myotonic Dystrophy market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Myotonic Dystrophy Unmet Needs, KOL’s views, Analyst’s views, Myotonic Dystrophy Market Access and Reimbursement

To know more about Myotonic Dystrophy companies working in the treatment market, visit @ Myotonic Dystrophy Clinical Trials and Therapeutic Assessment

Table of Contents

1. Myotonic Dystrophy Market Report Introduction

2. Executive Summary for Myotonic Dystrophy

3. SWOT analysis of Myotonic Dystrophy

4. Myotonic Dystrophy Patient Share (%) Overview at a Glance

5. Myotonic Dystrophy Market Overview at a Glance

6. Myotonic Dystrophy Disease Background and Overview

7. Myotonic Dystrophy Epidemiology and Patient Population

8. Country-Specific Patient Population of Myotonic Dystrophy

9. Myotonic Dystrophy Current Treatment and Medical Practices

10. Myotonic Dystrophy Unmet Needs

11. Myotonic Dystrophy Emerging Therapies

12. Myotonic Dystrophy Market Outlook

13. Country-Wise Myotonic Dystrophy Market Analysis (2022–2036)

14. Myotonic Dystrophy Market Access and Reimbursement of Therapies

15. Myotonic Dystrophy Market Drivers

16. Myotonic Dystrophy Market Barriers

17. Myotonic Dystrophy Appendix

18. Myotonic Dystrophy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679 Source: https://www.delveinsight.com/report-store.php
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/